Spaces:
Running
Running
File size: 23,250 Bytes
f688d5f |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 |
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Preserflo™ MicroShunt Presentation</title>
<!-- Tailwind CSS -->
<script src="https://cdn.tailwindcss.com"></script>
<!-- reveal.js -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.css">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/theme/sky.min.css" id="theme">
<!-- Font Awesome Icons -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
<style>
/* Custom Styles for Professional Look */
.reveal .slides section {
text-align: left; /* Default text alignment */
display: flex !important;
flex-direction: column;
justify-content: center; /* Center content vertically */
align-items: center; /* Center content horizontally */
min-height: 700px; /* Consistent slide height */
padding: 40px; /* Padding around slide content */
box-sizing: border-box;
}
.reveal .slide-content {
display: flex;
align-items: center; /* Vertically align items in the flex container */
justify-content: space-between; /* Space out text and visual content */
width: 100%; /* Full width within padding */
max-width: 1100px; /* Max width for content */
margin: auto; /* Center the content container */
}
.reveal .slide-content-vertical { /* For layouts where visual is above/below text */
flex-direction: column;
text-align: center;
}
.reveal .text-content {
flex: 1; /* Allow text content to take available space */
padding-right: 30px; /* Space between text and visual */
max-width: 60%; /* Limit text width for readability */
}
.reveal .text-content-full { /* For slides primarily text */
flex: 1;
width: 100%;
max-width: 900px; /* Wider max-width for text-heavy slides */
}
.reveal .visual-content {
flex-shrink: 0; /* Prevent visual content from shrinking */
width: 35%; /* Adjust visual content width */
text-align: center; /* Center images/icons */
}
.reveal .visual-content-full { /* For title slide visual */
width: auto;
margin-top: 2rem;
}
.reveal .visual-content i { /* Icon styling */
font-size: 7rem; /* Standard icon size */
color: #0ea5e9; /* Tailwind sky-500 */
margin-bottom: 1rem;
}
.reveal img.slide-image {
max-width: 100%;
max-height: 350px; /* Limit image height */
object-fit: contain; /* Ensure image scales nicely */
border-radius: 8px; /* Slightly rounded corners */
box-shadow: 0 4px 8px rgba(0,0,0,0.1); /* Subtle shadow */
}
.reveal h1 {
color: #ffffff; /* White for title slide */
font-size: 3.5em;
font-weight: bold;
margin-bottom: 0.5em;
}
.reveal h2 {
color: #0284c7; /* Tailwind sky-600 */
font-size: 2.5em;
font-weight: bold;
margin-bottom: 1em;
text-align: center;
width: 100%;
}
.reveal h3 {
color: #0369a1; /* Tailwind sky-700 */
font-size: 1.6em;
font-weight: bold;
margin-bottom: 0.8em;
}
.reveal h4 {
font-size: 1.2em;
color: #075985; /* Tailwind sky-800 */
font-weight: bold;
margin-bottom: 0.5em;
}
.reveal ul {
list-style: none;
padding-left: 0;
}
.reveal ul li {
font-size: 1.0em;
margin-bottom: 0.7em;
padding-left: 2em;
position: relative;
line-height: 1.4;
}
.reveal ul li::before {
content: "\f00c"; /* Font Awesome check icon */
font-family: 'Font Awesome 6 Free';
font-weight: 900;
color: #34d399; /* Tailwind emerald-400 */
position: absolute;
left: 0;
top: 4px;
font-size: 0.9em;
}
.reveal p {
font-size: 1.05em;
line-height: 1.5;
margin-bottom: 1em;
}
.reveal .citation {
font-size: 0.65em;
color: #6b7280; /* Tailwind gray-500 */
margin-top: 15px;
display: block;
text-align: right;
}
.reveal .slide-background-content { /* Default slide background */
background-color: #f0f9ff; /* Tailwind sky-50 */
}
/* Specific Slide Backgrounds */
.reveal section[data-background-color="#0ea5e9"] h1,
.reveal section[data-background-color="#0ea5e9"] p {
color: white;
}
.reveal section[data-background-color="#0ea5e9"] i {
color: white;
}
.comparison-grid {
display: grid;
grid-template-columns: 1fr 1fr;
gap: 20px;
width: 100%;
}
.comparison-grid h4 {
text-align: center;
margin-bottom: 1em;
}
.comparison-grid ul li::before {
top: 6px; /* Adjust icon position slightly */
}
</style>
</head>
<body>
<div class="reveal">
<div class="slides">
<!-- Slide 1: Title -->
<section data-background-color="#0ea5e9">
<div class="slide-content-vertical">
<h1>The Preserflo™ MicroShunt</h1>
<p class="text-2xl font-light">A Modern Surgical Solution for Glaucoma Management</p>
<div class="visual-content-full">
<i class="fas fa-eye text-7xl"></i>
</div>
</div>
</section>
<!-- Slide 2: What is Glaucoma? -->
<section class="slide-background-content">
<h2>Understanding Glaucoma</h2>
<div class="slide-content">
<div class="text-content">
<h3>The Challenge of IOP</h3>
<p>Glaucoma is a group of eye diseases often characterized by elevated Intraocular Pressure (IOP). [3, 6] This pressure rises when the eye's natural fluid (aqueous humor) doesn't drain properly due to blockage. [3, 8]</p>
<p>Sustained high IOP damages the optic nerve, responsible for sending visual information to the brain, which can lead to permanent vision loss. [2, 3, 6] The core goal of glaucoma treatment is effectively lowering IOP to preserve sight. [1, 7]</p>
<span class="citation">Sources: [1], [2], [3], [6], [7], [8]</span>
</div>
<div class="visual-content">
<i class="fas fa-tachometer-alt-fast"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram illustrating increased IOP and potential optic nerve damage]</p>
</div>
</div>
</section>
<!-- Slide 3: What is Preserflo? -->
<section class="slide-background-content">
<h2>Introducing Preserflo™ MicroShunt</h2>
<div class="slide-content">
<div class="text-content">
<h3>Device Overview</h3>
<p>The Preserflo™ MicroShunt is a tiny, soft, flexible tube, about 8-8.5mm long, designed specifically for glaucoma surgery. [2, 3, 7, 21] Its primary function is to safely lower eye pressure. [1, 2, 7]</p>
<p>It's crafted from SIBS (poly(styrene-block-isobutylene-block-styrene)), a highly biocompatible and inert material also used in coronary stents. [1, 2, 7, 24] This minimizes inflammation and the risk of rejection or degradation. [2, 3, 7, 23]</p>
<p>Features include stabilizing fins and a precise lumen diameter (70µm internal) designed to control fluid outflow. [1, 8, 13, 22] It is non-metallic and MRI/CT safe. [2, 3, 7]</p>
<span class="citation">Sources: [1], [2], [3], [7], [8], [13], [21], [22], [23], [24]</span>
</div>
<div class="visual-content">
<!-- Placeholder for actual image -->
<img src="https://via.placeholder.com/300x200.png?text=Preserflo+MicroShunt+Device" alt="Preserflo MicroShunt Device" class="slide-image">
<p class="mt-2 text-sm text-gray-600">[Placeholder: Actual image of the Preserflo MicroShunt]</p>
</div>
</div>
</section>
<!-- Slide 4: How it Works -->
<section class="slide-background-content">
<h2>Mechanism of Action</h2>
<div class="slide-content">
<div class="visual-content">
<!-- Placeholder for actual image/diagram -->
<img src="https://via.placeholder.com/300x300.png?text=Shunt+Placement+Diagram" alt="Diagram showing Preserflo placement and bleb formation" class="slide-image">
<p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram showing shunt placement and fluid flow to bleb]</p>
</div>
<div class="text-content pl-8">
<h3>Creating a New Pathway</h3>
<p>The MicroShunt acts as a bypass for the eye's natural, obstructed drainage system. [3, 6, 7, 13]</p>
<p>Implanted via an 'ab externo' approach, one end sits in the anterior chamber, accessing the excess aqueous humor. [1, 4, 6, 8] The other end channels this fluid out of the eye, directing it into the subconjunctival/sub-Tenon space. [2, 4, 8, 23]</p>
<p>This drained fluid forms a small, low-profile reservoir called a 'bleb' under the upper eyelid, where it is safely absorbed by surrounding tissues into the bloodstream, thus reducing IOP. [2, 3, 5, 7]</p>
<span class="citation">Sources: [1], [2], [3], [4], [5], [6], [7], [8], [13], [23]</span>
</div>
</div>
</section>
<!-- Slide 5: Indications -->
<section class="slide-background-content">
<h2>Who is a Candidate for Preserflo?</h2>
<div class="slide-content">
<div class="text-content">
<h3>Patient Suitability</h3>
<ul>
<li>Primarily indicated for Primary Open-Angle Glaucoma (POAG), including subtypes like pseudoexfoliation and pigmentary glaucoma. [1, 11, 18]</li>
<li>Patients whose IOP is not adequately controlled with maximal tolerated medications or laser therapy. [2, 7, 8, 11]</li>
<li>Individuals experiencing glaucoma progression that necessitates surgical intervention. [6, 8, 11]</li>
<li>Those who have difficulty with adherence to, or intolerance of, eye drop regimens. [7, 11]</li>
<li>May be considered for moderate-to-advanced glaucoma stages. [3, 10]</li>
</ul>
<p>Not suitable for angle-closure glaucoma, active infection, or severe dry eye. [1, 8, 13]</p>
<span class="citation">Sources: [1], [2], [3], [6], [7], [8], [10], [11], [13], [18]</span>
</div>
<div class="visual-content">
<i class="fas fa-user-check"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Image representing patient consultation or eye exam]</p>
</div>
</div>
</section>
<!-- Slide 6: The Procedure -->
<section class="slide-background-content">
<h2>The Implantation Procedure</h2>
<div class="slide-content">
<div class="visual-content">
<i class="fas fa-user-md"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Image or simple graphic of surgical setting/instruments]</p>
</div>
<div class="text-content pl-8">
<h3>Surgical Steps</h3>
<ul>
<li>Typically performed as an outpatient (day surgery) procedure. [2, 4, 6, 13]</li>
<li>Surgery duration is often around 30-45 minutes. [2, 21, 26]</li>
<li>Anesthesia options include local (injection or drops) or general anesthesia. [1, 2, 19]</li>
<li>Utilizes an 'ab externo' technique, familiar to glaucoma surgeons. [1, 22, 23]</li>
<li>Involves a conjunctival incision and careful dissection. [1, 2]</li>
<li>Mitomycin-C (MMC), an anti-scarring agent, is applied to enhance long-term success. [1, 2, 21, 17]</li>
<li>The MicroShunt is inserted, and the conjunctiva is closed, often with dissolvable stitches. [2, 3]</li>
</ul>
<span class="citation">Sources: [1], [2], [3], [4], [6], [13], [17], [19], [21], [22], [23], [26]</span>
</div>
</div>
</section>
<!-- Slide 7: Benefits -->
<section class="slide-background-content">
<h2>Benefits of Preserflo™ MicroShunt</h2>
<div class="slide-content">
<div class="text-content">
<h3>Key Advantages</h3>
<ul>
<li><strong>Significant IOP Lowering:</strong> Proven to effectively reduce eye pressure, with studies showing sustained results. [1, 4, 7, 20, 26]</li>
<li><strong>Less Dependence on Drops:</strong> Substantially reduces or eliminates the need for daily glaucoma medications for many patients. [2, 3, 6, 7, 8, 13, 16, 17, 20]</li>
<li><strong>Less Invasive Nature:</strong> Compared to trabeculectomy, the procedure is generally considered less invasive. [4, 6, 12, 13, 19, 23, 26]</li>
<li><strong>Favorable Safety Profile:</strong> Designed to minimize risks, with studies indicating lower rates of certain complications like hypotony vs. trabeculectomy. [4, 8, 9, 13, 19, 22, 26, 29]</li>
<li><strong>Potentially Faster Recovery:</strong> Patients may experience quicker visual recovery and return to normal activities. [6, 19, 22, 26]</li>
<li><strong>Predictability:</strong> Aims for more predictable IOP outcomes compared to trabeculectomy. [22]</li>
</ul>
<span class="citation">Sources: [1-4, 6-9, 12, 13, 16, 17, 19, 20, 22, 23, 26, 29]</span>
</div>
<div class="visual-content">
<i class="fas fa-shield-check"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Icon or graphic representing benefits/improvement]</p>
</div>
</div>
</section>
<!-- Slide 8: Preserflo vs. Trabeculectomy -->
<section class="slide-background-content">
<h2>Preserflo vs. Trabeculectomy: Comparison</h2>
<div class="text-content-full">
<h3>Why Preserflo Might Be Preferred</h3>
<div class="comparison-grid mt-4">
<div>
<h4 class="text-sky-700">Preserflo MicroShunt</h4>
<ul>
<li>Standardized device & procedure [1, 22]</li>
<li>Less invasive surgical technique [19, 23, 26]</li>
<li>Significantly lower risk of hypotony [5, 25, 28, 29]</li>
<li>Potentially fewer complications overall [5, 13, 26]</li>
<li>Fewer postoperative interventions (needling, etc.) in some studies [12, 23, 25]</li>
<li>Faster visual recovery suggested [19, 22, 26]</li>
<li>Better visual field preservation reported [5, 29]</li>
<li>More posterior bleb formation [15, 23]</li>
</ul>
</div>
<div>
<h4 class="text-sky-700">Trabeculectomy</h4>
<ul>
<li>Long-established "gold standard" [12, 23]</li>
<li>Requires manual scleral flap creation [14, 22]</li>
<li>Higher incidence of early hypotony [25, 28, 29]</li>
<li>Can have more early/late complications [5]</li>
<li>Often needs more intensive post-op management [12, 23, 25]</li>
<li>May achieve slightly lower IOP in some studies [14, 22, 29]</li>
<li>More anterior bleb [15, 23]</li>
</ul>
</div>
</div>
<p class="mt-6 text-center">Preserflo offers a balance of effective IOP control with an improved safety profile and potentially simpler recovery, making it an attractive alternative, especially where hypotony is a concern. [12, 19, 22, 25, 29]</p>
<span class="citation">Sources: [1, 5, 12-15, 19, 22, 23, 25, 26, 28, 29]</span>
</div>
</section>
<!-- Slide 9: Safety & Considerations -->
<section class="slide-background-content">
<h2>Safety & Important Considerations</h2>
<div class="slide-content">
<div class="text-content">
<h3>Potential Risks</h3>
<p>While designed for safety, potential surgical risks include:</p>
<ul>
<li><strong>IOP Fluctuations:</strong> Pressure may become too low (hypotony, often transient) or remain too high (hypertension), potentially requiring management. [1, 2, 3, 9, 13, 20, 21, 28]</li>
<li><strong>Bleeding (Hyphema):</strong> Usually minimal and resolves spontaneously; severe bleeding is rare. [2, 7, 9, 21]</li>
<li><strong>Infection (Endophthalmitis):</strong> A rare but serious lifelong risk associated with filtering blebs. [2, 3, 9, 13]</li>
<li><strong>Need for Re-intervention:</strong> Scarring or blockage may necessitate procedures like bleb needling or surgical revision. [1, 2, 3, 16, 20, 28, 29]</li>
<li><strong>Other Potential Issues:</strong> Transient blurred vision, shallow anterior chamber, choroidal effusion/detachment, cataract progression, rare shunt exposure or migration. [1, 2, 3, 9, 20]</li>
</ul>
<p>Regular post-operative monitoring is crucial for optimal outcomes. [2, 3, 5]</p>
<span class="citation">Sources: [1-3, 5, 7, 9, 13, 16, 20, 21, 28, 29]</span>
</div>
<div class="visual-content">
<i class="fas fa-exclamation-triangle text-yellow-500"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Icon representing caution or safety check]</p>
</div>
</div>
</section>
<!-- Slide 10: Conclusion -->
<section class="slide-background-content">
<h2>Conclusion: Preserflo™ in Modern Glaucoma Care</h2>
<div class="slide-content">
<div class="visual-content">
<i class="fas fa-graduation-cap"></i>
<p class="mt-2 text-sm text-gray-600">[Placeholder: Graphic representing innovation or forward-thinking]</p>
</div>
<div class="text-content pl-8">
<h3>Key Takeaways</h3>
<p>The Preserflo™ MicroShunt is an innovative surgical device offering a significant evolution in glaucoma treatment. [19]</p>
<ul>
<li>Provides effective and sustained IOP reduction, comparable to trabeculectomy in many cases, while reducing reliance on eye drops. [1, 12, 14, 17, 20]</li>
<li>Features an enhanced safety profile, notably lower rates of hypotony and potentially fewer overall complications compared to trabeculectomy. [1, 9, 19, 23, 28, 29]</li>
<li>Offers potential benefits of a less invasive procedure, faster recovery, and simpler post-operative management. [12, 19, 23, 25, 26]</li>
</ul>
<p>It represents a valuable and reliable option for surgeons and patients seeking effective IOP control with improved safety and predictability in the management of open-angle glaucoma. [1, 19, 22, 23]</p>
<span class="citation">Sources: [1], [9], [12], [14], [17], [19], [20], [22], [23], [25], [26], [28], [29]</span>
</div>
</div>
</section>
</div>
</div>
<!-- reveal.js -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/notes/notes.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/markdown/markdown.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/highlight/highlight.min.js"></script>
<script>
Reveal.initialize({
hash: true, // Enables deep linking to slides
plugins: [ RevealMarkdown, RevealHighlight, RevealNotes ] // Basic plugins
});
</script>
</body>
</html> |